Diabetes Care, Vol 18, Issue 3 388-392, Copyright © 1995 by American Diabetes Association

ARTICLES

Feasibility of intraperitoneal insulin therapy with programmable implantable pumps in IDDM. A multicenter study. The EVADIAC Study Group. Evaluation dans le Diabete du Traitement par Implants Actifs

H Hanaire-Broutin, C Broussolle, N Jeandidier, E Renard, B Guerci, MJ Haardt and V Lassmann-Vague
Hopital Rangueil, Toulouse, France.

OBJECTIVE--To report the overall French experience, obtained through the collaboration of seven centers (EVADIAC [Evaluation dans le Diabete du Traitement par Implants Actifs] register), on the safety, feasibility, and efficacy of intraperitoneal insulin therapy by programmable implantable pumps, using three different devices. RESEARCH DESIGN AND METHODS--This is a multicenter prospective study involving 224 type I diabetic patients implanted with a programmable implantable pump (cumulative follow-up: 353 patient-years; mean duration: 1.5 +/- 0.9 years [mean +/- SD]. The Infusaid and the Promedos devices are equipped with a side port and refilled with U100 insulin (Hoechst 21 PH); the Minimed pump is not equipped with a side port and is refilled with U400 insulin (Hoechst 21 PH). Metabolic data and adverse events were recorded in a central register run by EVADIAC. RESULTS--A total of 29 local pump-pocket events (8/100 patient-years) and 9 pump failures (2.5/100 patient-years) occurred. The major technical problems were 1) pump flow rate reduction related to insulin aggregates, reversible after alkaline rinsing of the pump, and 2) 47 catheter obstructions requiring laparoscopic or conventional surgery. Pump therapy was abandoned in only 11 patients. HbA1c (7.4 +/- 1.8 vs. 6.8 +/- 1.0%, P < 0.001), mean glycemia (8.7 +/- 1.5 vs. 7.8 +/- 1.0 mmol/l, P < 0.001), and blood glucose SDs (3.8 +/- 0.8 vs. 3.3 +/- 0.8 mol/l, P < 0.001) decreased significantly after 6 months and remained lower than baseline thereafter. CONCLUSIONS--Intraperitoneal insulin infusion using an implantable programmable pump is a feasible and relatively safe technique that may improve metabolic control and glycemic stability. Long-term studies, however, are needed to demonstrate whether or not the improvement in glycemic control could be sustained for several years.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				N. Jeandidier, S. Boullu, M.-S. Busch-Brafin, G. Chabrier, R. Sapin, F. Gasser, and M. Pinget Comparison of Antigenicity of Hoechst 21PH Insulin Using Either Implantable Intraperitoneal Pump or Subcutaneous External Pump Infusion in Type 1 Diabetic Patients Diabetes Care, January 1, 2002; 25(1): 84 - 88. [Abstract] [Full Text] [PDF]

				L. Kessler, S. Tritschler, A. Bohbot, S. Sigrist, V. Karsten, S. Boivin, P. Dufour, A. Belcourt, and M. Pinget Macrophage Activation in Type 1 Diabetic Patients With Catheter Obstruction During Peritoneal Insulin Delivery With an Implantable Pump Diabetes Care, February 1, 2001; 24(2): 302 - 307. [Abstract] [Full Text]

				H. Gin, V. Melki, B. Guerci, and B. Catargi Clinical Evaluation of a Newly Designed Compliant Side Port Catheter for an Insulin Implantable Pump: The EVADIAC experience Diabetes Care, January 1, 2001; 24(1): 175 - 175. [Full Text]